Kornimate/medical-research-clean huggingface dataset:
electrocardiogram-based artificial intelligence-assisted detection of heart disease

Conditions: Atrial Fibrillation; Structural Heart Disease

Summary: atrial fibrillation is an abnormal beating of the heart that can lead to stroke or heart failure. structural heart diseases are conditions that affect the heart valves or heart muscle and can cause permanent heart damage if left untreated. sometimes people have atrial fibrillation or structural heart disease and do not know it. the purpose of this study is to evaluate two devices that can predict who has or may develop atrial fibrillation or structural heart disease based on the results of an electrocardiogram.


Eligibility criteria:
inclusion criteria: * retrospective phase: * adults aged 40 or older. * at least 1 ecg obtained during routine clinical care. * prospective phase: * af cohort: * adults aged 65 or older at the time of ecg. * ecg obtained as part of a clinical care. * patient is able to identify a licensed healthcare provider to receive the results of the patch monitor. * shd cohort: * adults aged 40 or older at the time of the ecg. * ecg obtained as part of a clinical care between study start date and the end of study recruitment * patient is able to identify a licensed healthcare provider to receive the results of the echocardiogram. exclusion criteria: * retrospective phase: * patients who have previously requested that their data not be involved in any secondary use application such as a research study. * prospective phase: * af cohort: * any clinical or social factor that would prohibit completing the follow-up studies in a timely fashion. * patient currently admitted to the hospital (at time of consent) * permanent pacemaker or implanted cardiac defibrillator or implanted loop recorder. * history of atrial fibrillation or atrial flutter. * cardiac surgery within 30 days prior to the index ecg * cardiac surgery planned within the next 6 months. * allergy to adhesive. * shd cohort: * any clinical or social factor that would prohibit completing the follow-up studies in a timely fashion. * patient currently admitted to the hospital (at time of consent). * history of shd defined as any of the following: severe mitral regurgitation, severe tricuspid regurgitation, moderate or severe aortic stenosis, moderate or severe aortic regurgitation, moderate or severe mitral stenosis, left ventricular systolic dysfunction (lvef ≤ 40%), or increased septal wall thickness \> 15 mm. * allergy to ultrasound gel.

Keywords: heart disease structural heart disease machine learning electrocardiogram atrial fibrillation
3d resin printed fracture models for anatomy education

Conditions: Educational Problems; Anatomical Pathological Condition

Summary: resin printing is an emerging technology with a wide array of applications. this research seeks to assess the practicality of incorporating 3d resin printed models into anatomy education while investigating how fractured models impact students' decision-making and quiz scores.

over the past decade, 3d printing has become increasingly accessible and cost-effective, offering systems and materials suitable for home use. 3d printing is a technology that streamlines production by translating computer-generated models into physical objects, layer by layer. in comparison to other tissue engineering and rapid prototyping methods, 3d printing boasts numerous advantages, such as exceptional precision, rapid production, cost-effectiveness, and seamless integration. utilizing 3d models can significantly enhance the comprehension of intricate structures for medical professionals and students alike. common materials used in 3d printing include robust nylon, aluminum, gypsum, textile components, polylactic acid, and resin. among these, photosensitive resin stands out, as it enables the creation of higher-quality, more intricate structures that closely resemble real tissues, offering a smoother finish devoid of visible raw material textures. this study's primary objective was to assess the suitability of tissues produced by a 3d resin printer in anatomy education, with the aim of enhancing hands-on training through direct manipulation of fractured bone models.

Eligibility criteria:
inclusion criteria: * having stereopsis above 40 arc/seconds according to the titmus stereopsis test exclusion criteria: * having partial or total vision loss * having a history of traumatic injury to the upper extremities within the last six months * having used wrist anatomy models in virtual or real environments
clinical investigation of the nucleus® ci532 cochlear implant

Conditions: Hearing Loss

Summary: the aim of this study is to investigate the clinical benefit for patients implanted with the nucleus® ci532 cochlear implant and to demonstrate the atraumatic nature of the electrode design. nucleus® ci532 has a pre-curved, perimodiolar array, the ea32, which is introduced into the cochlea through a straightening sheath.


Eligibility criteria:
inclusion criteria: * eighteen years of age or older at the time of implantation * conventional candidate for cochlear implantation with a perimodiolar electrode array according to local criteria (excepting the exclusion criteria that follow) * native speaker in the local language used to assess clinical performance exclusion criteria: * evidence of hearing loss prior to 5 years of age * prior cochlear implantation; i.e. having a cochlear implant in the contralateral ear, or previously implanted in either ear * medical or psychological conditions that contraindicate undergoing general anaesthesia or surgery * ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by medical examination * hearing impairment due to lesion or neuropathy of the acoustic nerve, viii nerve or central auditory pathway * active middle-ear infection * tympanic membrane perforation * unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices * unwillingness or inability of the candidate to comply with all investigational requirements such as undergoing a post-operative digital volume tomography/conebeam scan * patients with existing cerebral spinal fluid shunts or drains, existing perilymph fistula, skull fracture or cerebral spinal fluid leak * patients with recurrent episodes of bacterial meningitis * pregnancy or breast-feeding * known allergies to components of the implant * wearing other active implants with known interference with cochlear implants
a study of two anti-hiv drug combinations

Conditions: HIV Infections

Summary: the purpose of this study is to compare the safety and effectiveness of taking lamivudine (3tc) plus zidovudine (zdv) plus a protease inhibitor (pi) with taking the 3tc/zdv combination tablet (combivir) plus a pi. this study also examines how well patients follow the dosing schedules for these drugs. doctors believe that taking combivir plus a pi may be as effective as taking 3tc plus zdv plus a pi.

it is hypothesized that a fixed-dose 3tc/zdv tablet given bid in combination with a protease inhibitor is clinically equivalent in its effect on plasma hiv-1 rna level to a conventional regimen of 3tc, zdv, and a protease inhibitor. patients are stratified according to their current protease inhibitor therapy and randomized to receive open-label therapy of 1 combivir tablet bid (arm ii) or an equivalent dose of 3tc and zdv (arm i), plus their current protease inhibitor for 16 weeks.

Eligibility criteria:
inclusion criteria patients must have: * hiv infection documented by a licensed antibody elisa assay and confirmed by western blot, positive hiv blood culture, positive hiv serum antigen, or plasma viremia. * cd4+ cell count of at least 300 cells/mm3. * hiv-1 rna less than 10,000 copies/ml by roche amplicor pcr assay. * cdc category a or b classification for hiv infection (no clinical diagnosis of aids). * compliance with dosing schedule and protocol evaluations. prior medication: required: * 3tc at 150 mg bid, zdv at 600 mg/day (200 mg tid or 300 mg bid), plus a marketed protease inhibitor (ritonavir, saquinavir, indinavir, or nelfinavir) at its recommended dose for at least 10 weeks. allowed: * inhaled corticosteroids for the treatment of asthma. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * malabsorption syndromes affecting drug absorption (e.g., crohn's disease and chronic pancreatitis). * enrollment in other investigational protocols. concurrent medication: excluded: * cytotoxic chemotherapeutic agents. * nonnucleoside reverse transcriptase inhibitors. * other investigational agents. concurrent treatment: excluded: radiation therapy. prior medication: excluded: * cytotoxic chemotherapeutic and immunomodulating agents such as systemic corticosteroids, if-2, alpha-ifn, beta-ifn, or gamma-ifn (except for inhaled corticosteroids for the treatment of asthma) within 4 weeks of study entry. * hiv immunotherapeutic vaccine within 3 months of study entry. prior treatment: excluded: radiation therapy within 4 weeks of study entry.

Keywords: drug therapy, combination zidovudine hiv protease inhibitors cd4 lymphocyte count cd4-cd8 ratio lamivudine patient compliance reverse transcriptase inhibitors anti-hiv agents viral load
evaluation of adherence to the mediterranean diet in patients with recurrent renal stones and disease osteometabolic

Conditions: Renal Stones; Osteometabolic Disease

Summary: the aim of this research protocol is to evaluate the adherence to the mediterranean diet in patients suffering from recurrent kidney stones and osteometabolic diseases. results of the study will allow to assess the dietary habits of patients with the above diseases. given the universal prevalence of nephrolithiasis and osteometabolic diseases, the knowledge of these data appears crucial for the proper management of the dietary approach to prophylaxis secondar


Eligibility criteria:
inclusion criteria: * patients with idiopathic relapsing nephrolithiasis with evidence instrumental of bilateral renal stones or emission of more than one stone in the past 5 years exclusion criteria: * patients who had albumin-corrected plasma calcium levels \> 11.0 mg/dl at the time of the first determination of serum levels of 25 oh vitamin d; * patients who had glomerular filtration rate \< 60 ml/min/1.73 m2; * patients who had positive personal history of chronic granulomatous disease; * pregnancy patients; * positive personal history for morphological abnormalities of the excretory system; * incomplete data collection.
superior capsule vs bridging study

Conditions: Rotator Cuff Tears

Summary: randomized controlled trial examining superior capsule reconstruction versus tendon repair with graft interposition in "irreparable" rotator cuff tears.

rct n = 50 groups: 1. bridging 2. scr outcomes: 1. worc 2. ases 3. quickdash 4. mri at 12 months post-op

Eligibility criteria:
inclusion criteria: 1. large to massive rotator cuff tear (with or without subscapularis tear) that may possibly be irreparable without the use of graft materials (confirmed intra-operatively) 2. either primary tear or re-tear after previous repair 3. radiographic evidence of hamada stage 1-3, with or without samilson \& prieto mild osteoarthritis (\<3mm inferior osteophyte) exclusion criteria: 1. primary glenohumeral osteoarthritis: radiographic evidence of samilson \& prieto classification moderate or greater 2. cuff tear arthropathy (cta): radiographic evidence of hamada stage 4 or above 3. inflammatory joint disease of the shoulder (e.g. rheumatoid arthritis) 4. medical issues precluding surgery 5. unwilling or unable to complete study outcomes 6. worker's compensation claim or litigation

Keywords: irreparable
an evaluation of a collagen dressing to treat chronic, stalled lower-extremity wounds

Conditions: Wound

Summary: patients who meet the inclusion criteria will be provided with fibrillar collagen powder dressing. the powder dressing will be used in accordance with its label. after cleansing the wound by the clinical site staff, the powder is placed directly on the wound, and then the wound will be covered with an appropriate moisture retentive secondary dressing. patients will visit the clinic twice a week to have the powder re-applied. wound evaluations will take place once a week at the outpatient clinic, with the intervention lasting up to twelve weeks. concurrent standard of care, such as compression for venous ulcers, will be provided.


Eligibility criteria:
inclusion criteria: * has one of the following types of wounds below the knee: diabetic ulcers, pressure ulcers, venous ulcers, ulcers of mixed-vascular origin, traumatic wounds, or post-surgical wounds * wound has been present for at least four weeks * wound is free of necrotic tissue or debridement practices will take place prior to initial visit in order to remove necrotic tissue * wound has failed at least one wound care treatment * wound size is between 1 and 100 square centimeters * patient has adequate circulation as demonstrated by biphasic or triphasic doppler waveform, measured within three months prior to study enrollment. if monophasic on exam, then non-invasive tests must display ankle brachial index greater than 0.8 and no worse than mild disease on segmental pressures. * wound is confirmed as being free of infection and absence of osteomyelitis exclusion criteria: * pregnant, planning to become pregnant during the study timeframe, or breast feeding * unable or unwilling to receive porcine collagen * wound is infected or presence of osteomyelitis * allergy or sensitivity to collagen * inability, in the opinion of the investigator to follow protocol requirements, attend follow up visits in a timely manner, or otherwise comply with the requirements of the protocol
follow-up protocol for patients with cancer/aids/skin disease

Conditions: Melanoma; Ovarian Cancer; Prostate Cancer; Breast Cancer; Lymphoma

Summary: this protocol is to provide follow-up medical/surgical visits for dcs patients who are long term survivors and may not currently be a participant entered on an active research protocol. no investigational treatments or standard treatments will be administered on this protocol.

background: * patients enrolled on ccr clinical protocols may require long term follow-up to assess outcome (e.g., survival) or the effects of prior therapy. * keeping the primary treatment protocols open after accrual is complete in order to follow patients for long term outcome is an administrative burden on investigators and the irb. objectives: -to provide follow-up for patients who are long term survivors previously enrolled center for cancer research (ccr) trial but who may not currently be enrolled on a research protocol. eligibility: -patients who were previously enrolled on a ccr protocol and who are not eligible for an active nci intramural primary research protocol. design: * the medical procedures/tests will be based on the patient's diagnosis, treatment and supporting clinical information. this is a follow-up study in which only standard tests and procedures are to be performed. * clinical information that is relevant to the patients prior protocols will be collected for research purposes. * procedures that entail more than minimal risk to the patient should not be performed for research purposes on this protocol.

Eligibility criteria:
* eligibility criteria: patients of any age who were previously enrolled on a ccr protocol. not eligible for or unwilling to participate in an active nci intramural primary research protocol. ccr investigator decides it is in the best interests of the patient and the cc for the patient to be seen in follow-up visits at the nih. patient or legally authorized representative (lar)/guardian is able to provide informed consent.

Keywords: cancer late-effects survival follow-up natural history
is it necessary to drain in contact with the prostheses during a cure of a ventricle with retromuscular prosthesis?

Conditions: Eventration of the Abdominal Wall

Summary: is there an indication for drainage in contact with a prosthesis placed in a retromuscular position, during a cure for abdominal wall ventration in adults? this procedure is very frequent in digestive surgery and can be associated with serious complications, notably prosthesis infection.


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * patient operated on at hus between 01/01/2018 and 12/31/2020 * patient who has undergone surgical cure of anterior or lateral abdominal wall eventration of any width with placement during the procedure of a prosthetic mesh in a prefascial retromuscular position. * patient not objecting to the reuse of their data for scientific research purposes. exclusion criteria: * patient who has expressed opposition to the reuse of his or her data for scientific research purposes. * particular clinical forms of the disease: absence of previous surgical intervention (and thus absence of ventration: umbilical hernia, diastasis) * absence of prosthesis during the operation or prosthesis placed in intraperitoneal position

Keywords: eventration of the abdominal wall hernia drainage retromuscular position digestive surgery
pilot social network weight loss intervention

Conditions: Diet, Healthy; Weight Loss

Summary: specific aim #1: pilot test a social network-informed cbpr-derived health promotion program for feasibility outcomes with overweight or obese adults from two immigrant communities. specific aim #2: assess the preliminary impact of embedding a social network-informed cbpr-derived intervention within a regional health promotion resource hub on sustainability and uptake outcomes.

the intervention will consist of 12 community-based mentoring and education sessions, group activities and application of a community toolkit for healthy weight loss delivered by trained interventionists from hispanic and somali communities to their social networks. using a pre-post study design, 4 social networks of adults with approximately 32 network participants will receive the intervention. primary outcomes, measured 3 months after implementation, will include feasibility measures of acceptability, implementation, and practicality. secondary outcomes will include bmi, waist circumference, blood pressure, fasting blood glucose, total cholesterol, physical activity level, dietary change, and health-related quality of life. eligibility criteria include (1) self-identification as hispanic or somali, (2) member of an hps social network, (3) age≥18 and \<65 (4) willingness to participate in all aspects of the study; and (5) provision of informed consent. exclusion criteria include (1) pregnancy at the time of enrollment and (2) serious medical conditions or disabilities that would make physical activity difficult. we will test how best to integrate a social network intervention within an existing evidence-based regional health promotion infrastructure (wellconnect) that will enhance its potential dissemination and community-wide uptake

Eligibility criteria:
inclusion criteria: 1. self-identification as hispanic or somali 2. member of an hps social network 3. age≥18 and \<65 4. willingness to participate in all aspects of the study 5. provision of informed consent. exclusion criteria: 1. pregnancy at the time of enrollment 2. serious medical conditions or disabilities that would make physical activity difficult. * to avoid stigmatization, a normal weight (bmi\<25) will not exclude individuals from participating, but they will be excluded from the measurements and analyses.
femoral nerve block vs peri-capsular nerve group block for hip fracture analgesia

Conditions: Spinal Anesthesia; Analgesia; Hip Fractures

Summary: the purpose of the study is to compare the analgesic efficacy of femoral nerve block and peri-capsular nerve group block administered before spinal anesthesia for positioning to spinal anaesthesia in patients undergoing surgery for hip fracture and to evaluate the efficacy for postoperative analgesia

spinal anesthesia is commonly used in patients undergoing hip fracture surgery. however the procedure of patient positioning to perform a spinal block is painful and may require the administration of iv analgesics or some regional anesthesia techniques such as femoral nerve block, fascia-iliaca compartment block, peri-capsular nerve group block. at the study, the investigators aimed to compare analgesic efficacy of femoral nerve block and peri-capsular nerve group block administered before spinal anesthesia for positioning to spinal anaesthesia in patients undergoing surgery for hip fracture and to evaluate the efficacy for postoperative analgesia.

Eligibility criteria:
inclusion criteria: * patients with hip fracture scheduled for surgery under spinal anesthesia. exclusion criteria: * hemorrhagic diathesis, * peripheral neuropathy, * allergy to local anesthetics, * mental disorders, * use of analgesics for 8 h before the performance of spinal block
study of sumatriptan succinate injection kit in patients with migraine or cluster headache in japan

Conditions: Migraine Disorders

Summary: this study will be conducted to collect cases treated by self-injection of sumatriptan 3mg kit product for the treatment of migraine or cluster headache attacks in clinical settings, to demonstrate the efficacy, and to examine patient acceptability (simplicity and usefulness) and rate of successful self-injection.


Eligibility criteria:
inclusion criteria: * diagnosis of migraine (with or without aura) or cluster headache according to the international classification of headache disorders, version 2 (ichd-ii) * history of migraine or cluster headache persisting for at least 6 months * migraine: one to 6 attacks of moderate or severer headaches per month during the 2 months prior to enrollment * cluster headache: each attack persisting for at least 45 minutes * written informed consent obtained from the patient. when a patient is a minor, written informed consent from his/her proxy consenter (e.g., person with parental authority) will also be required. exclusion criteria: * history of hypersensitivity to any of the ingredients of 5-ht1b/1d receptor antagonists (e.g., triptans) or serious ae due to treatment with these drugs * history of serious adverse event attributable to treatment with imigran® injection 3 * history of myocardial infarction, current or previous history of ischemic heart disease or its symptoms/signs, or current history of atypical variant angina (coronary arteriospasm) * previous history of cerebrovascular disorder or transient cerebral ischemic attack * current or previous history of peripheral angiopathy (including raynaud's syndrome) * systolic blood pressure (sbp) \>160 mmhg or diastolic blood pressure (dbp) \>95 mmhg at the start of treatment period * current familial hemiplegic migraine, basilar migraine, or sporadic hemiplegic migraine * current abuse of ergotamine- or dihydroergotamine-containing preparations or triptans * pregnant women, lactating mothers, women who may be pregnant, or women of childbearing potential using no appropriate contraceptive measures. * epilepsy or organic cerebral disorder which may lead to convulsion * previous history of hypersensitivity to sulfonamides * known drug allergy or idiosyncrasies * known drug dependency or alcoholism

Keywords: migraine sumatriptan succinate injection kit cluster headache self-injection